In a recent published report, Kenneth Research has updated the market report for Monogenetic Disease Therapy Market for 2021 till 2030. Report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In the view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to be regain 25% by the end of 2021- Positive Growth in the economic demand and supply.
U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Monogenetic Disease Therapy Market products.
Request To Download Sample of This Strategic Report: https://www.kennethresearch.com/report-details/monogenetic-disease-therapy-market/10220969
Kenneth Research has recently added a report titled Monogenetic Disease Therapy Market in its storehouse of market research reports. The report provides a detailed insight into the market scenario on the basis of the market size and volume for the forecast period, i.e., 2021 2030. Factors such as the growing advancements in the development of novel drugs, coupled with the growing health infrastructure in several nations worldwide are anticipated to drive the growth of the market in the coming years. Moreover, increasing expenditure on healthcare, backed by the need amongst individuals for quality healthcare services, is also anticipated to contribute to the market growth.
According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 9.08% in 2001 to 9.84% in 2018. Additionally, the current health expenditure per capita (current US$) increased from USD 492.99 in 2001 to USD 1110.84 in 2018. Moreover, growing concern for deaths caused due to various diseases and the need for treatment that can lower the crude death rate, which in the year 2019 recorded close to 7% (per 1000 people), are also anticipated to drive the market growth during the forecast period.
Monogenetic diseases result from the mutation or change in the DNA sequence of one gene. A mutated gene hinders the normal functioning of the protein present in its composition and hence results in various types of monogenetic disorders such as cystic fibrosis, sickle cell disease, Gaucher disease, SCID and others.
“The Final Report will cover the impact analysis of COVID-19 on this industry.”
Request To Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10220969
The monogenetic disease therapy market is expected to grow during the forecast period, due to a rise in the incidence of monogenetic diseases, coupled with advancement in treatment technologies.
Themonogenetic disease therapy market is expected to grow during the forecast period, due to the rising prevalence of monogenetic diseases globally. According to the World Health Organization (WHO), the global prevalence of all monogenetic diseases at birth is approximately 10/1000. Increased research activities and clinical trials on monogenic diseases and its therapeutic treatments are further anticipated to drive the monogenetic diseases therapy market.
According to NCBI, monogenetic diseases were the second most popular indication of gene therapies after cancer, accounted for 10% of the total gene therapy trials conducted between 1989 and 2015.
Other driving factors for the growth of monogenetic disease therapy market include rising awareness towards genetic diseases, coupled with the presence of key healthcare market players such as Sanofi, Bayer AG, Pfizer Inc., and others who are determined to develop innovative therapies, advanced bio-instruments, and vaccines to treat monogenetic diseases.
However, high therapy cost and lower commercial success rates of treatments like gene therapy can restrain the growth of global monogenetic disease therapy market.
By Inheritance Pattern
On the basis of inheritance pattern, autosomal monogenetic diseases therapy market is expected to grow at a faster pace, due to rise in a number of autosomal monogenetic diseases like Cystic fibrosis (a most common type of monogenetic disease), Tay Sachs disease and Sickle cell anemia.
According to the European Lung White Book, one in 25 people of European descent carries one mutant allele of CFTR, and one person among 2000-3000 people is affected by cystic fibrosis. Chromosomal disease therapy is also expected to grow during the forecast period, owing to the rising incidence of hemophilia, hunter disease, and others. Haemophilia is estimated to be afflicted in 1 in 10,000 people globally.
By Therapy Type
Pharmacological and surgical therapies for treating monogenetic diseases are predicted to dominate the global market, due to their higher preference among patients. For instance, in February 2018, the U.S. FDA approved a combination of ivacaftor and tezacaftor, developed by Vertex Pharmaceutical, to treat cystic fibrosis. Gene therapy is another therapy segment which is expected to witness a rapid growth over the forecast period, owing to its efficiency in the treatment of monogenetic diseases like CF and SCID.
For instance, Glybera, which is the first clinically approved gene therapy in the European Union, uses an adeno-associated virus (AAV) vector drug for correction of lipoprotein lipase deficiency and to correct cystic fibrosis, it uses repeated nebulization of liposomes encoding the cystic fibrosis transmembrane conductance regulator (CFTR).
Key market players operating in global monogenetic disease therapy market include Abbott Laboratories, BAG Healthcare Gmbh, Novartis, Pfizer Inc., Vertex Pharmaceuticals, Bristol-Myers Squibb, F. Hoffmann-La Roche Limited, Bayer AG, Grifols S.A, Bluebird Bio, UniQure, and Sanofi S.A.
Market players, clinical research organizations and hospitals are focusing on collaborations to develop and commercialize therapies for the treatment of monogenetic diseases.
For instance, in August 2018, Mustang Bio, a U.S. based pharmaceutical firm entered into an exclusive license agreement with St. Jude Children’s Research Hospital to develop the ex-vivo lentiviral gene therapy for X-linked SCID (commonly known as Bubble Boy Disease) treatment. Through this merger, Mustang Bio aims to expand their pipeline into gene therapy for patients with X-SCID.
About Kenneth Research:-
Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation
Email : Sales@kennethresearch.com